Twenty-nine state attorneys general filed a lawsuit against Bristol-Myers Squibb June 4 alleging the company illegally prevented sales of generic Taxol (paclitaxel). According to the states, sales of Taxol total over $5.4 bil. since 1998 when Hatch-Waxman marketing exclusivity for the drug ended...
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.